乌帕替尼与优特克单抗治疗溃疡性结肠炎的比较疗效：一项多中心回顾性队列研究 - Suppr | 超能文献

相似文献

1

Comparative Effectiveness of Upadacitinib vs Ustekinumab for Ulcerative Colitis: A Multicenter Retrospective Cohort Study.乌帕替尼与优特克单抗治疗溃疡性结肠炎的比较疗效：一项多中心回顾性队列研究

Clin Gastroenterol Hepatol. 2024 Mar;22(3):666-668. doi: 10.1016/j.cgh.2023.08.021. Epub 2023 Sep 5.

2

Persistence, Effectiveness, and Safety of Upadacitinib in Crohn's Disease and Ulcerative Colitis in Real Life: Results From a Spanish Nationwide Study (Ureal Study).乌帕替尼在克罗恩病和溃疡性结肠炎中的真实生活持久性、有效性及安全性：一项西班牙全国性研究（Ureal研究）的结果

Am J Gastroenterol. 2024 Nov 26;120(7):1593-1604. doi: 10.14309/ajg.0000000000003243.

3

Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.对接受8周诱导治疗有反应的中度至重度活动性溃疡性结肠炎患者进行乌帕替尼维持治疗的疗效和安全性（U-ACHIEVE维持治疗）：随机、安慰剂对照、双盲3期维持研究的总体结果

Lancet Gastroenterol Hepatol. 2023 Nov;8(11):976-989. doi: 10.1016/S2468-1253(23)00208-X. Epub 2023 Sep 9.

4

Comparative Effectiveness of Upadacitinib and Tofacitinib in Ulcerative Colitis: A US Propensity-Matched Cohort Study.乌帕替尼与托法替布治疗溃疡性结肠炎的疗效比较：一项美国倾向匹配队列研究。

Am J Gastroenterol. 2024 Dec 1;119(12):2471-2479. doi: 10.14309/ajg.0000000000002947. Epub 2024 Jul 5.

5

Effectiveness of Ustekinumab for Patients With Moderate-to-Severe Ulcerative Colitis: A Multicenter Real-World Canadian Study.乌司奴单抗治疗中重度溃疡性结肠炎患者的有效性：一项加拿大多中心真实世界研究。

Am J Gastroenterol. 2024 Nov 14;120(7):1576-1584. doi: 10.14309/ajg.0000000000003212.

6

Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons.对比乌帕替尼、维得利珠单抗、乌司奴单抗和托法替布在溃疡性结肠炎诱导缓解和维持治疗后的疗效和安全性：三项匹配调整间接比较。

Adv Ther. 2024 Oct;41(10):3832-3849. doi: 10.1007/s12325-024-02912-y. Epub 2024 Aug 10.

7

Long-Term Effectiveness and Safety of Ustekinumab Dose Escalation in Patients with Moderate-to-Severe Ulcerative Colitis: A Multicenter Retrospective Cohort Study.乌司奴单抗剂量递增疗法用于中重度溃疡性结肠炎患者的长期有效性及安全性：一项多中心回顾性队列研究

Dig Dis Sci. 2025 Mar 17. doi: 10.1007/s10620-025-08977-1.

8

Clinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study.乌帕替尼诱导治疗溃疡性结肠炎后的临床和内镜结果：一项多中心回顾性队列研究

Inflamm Bowel Dis. 2024 Jul 3;30(7):1207-1210. doi: 10.1093/ibd/izad155.

9

Comparative Speed of Early Symptomatic Remission With Advanced Therapies for Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.比较中重度溃疡性结肠炎的早期症状缓解速度与先进治疗方法：系统评价和网络荟萃分析。

Am J Gastroenterol. 2023 Sep 1;118(9):1618-1625. doi: 10.14309/ajg.0000000000002263. Epub 2023 Mar 29.

10

The Successful Use of Upadacitinib as Monotherapy for Hidradenitis Suppurativa and Ulcerative Colitis in the Setting of Refractory Disease.乌帕替尼作为单一疗法成功用于治疗难治性化脓性汗腺炎和溃疡性结肠炎。

Pediatr Dermatol. 2025 Mar-Apr;42(2):353-357. doi: 10.1111/pde.15759. Epub 2024 Sep 11.

引用本文的文献

1

Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations.用于炎症性肠病的白细胞介素-23抑制剂：关键试验与实际考量

Curr Gastroenterol Rep. 2025 Jun 4;27(1):35. doi: 10.1007/s11894-025-00987-3.

2

Unlocking the power of probiotics, postbiotics: targeting apoptosis for the treatment and prevention of digestive diseases.释放益生菌、后生元的力量：针对细胞凋亡治疗和预防消化系统疾病。

Front Nutr. 2025 Mar 31;12:1570268. doi: 10.3389/fnut.2025.1570268. eCollection 2025.

3

Efficacy and Safety of Janus Kinase-Inhibitors in Ulcerative Colitis.